Our team has made tremendous progress in two years. Our biggest achievement was recieving funding for a clinical trial with the University of Maryland Medical Center Maternal Fetal Medicine Department. We have a prototype of the GlucoseMama Kit scheduled for a pilot test in March 2018 with the Maternal Fetal Medicine Associates of Maryland. We are reaching out to hospitals and healthcare systems for more pilots. The response from the medical community has been overwhelmingly positive. Patients and doctors love our system. Compliance with blood glucose logging among our beta testers is extremely high. One of the many quotes from our beta testers reads: “I really like everything about it. Overall, I like the feel of the app. Communication between patient and MD is very important to me.” And, one of the MFM specialists we work with said she would like to see the GlucoseMama Kit become the standard of care. That’s our goal, too!
Dr, MD OBGYN FACOG
Biography: Dr. Teresa Knight, OBGYN, FACOG is the co-founder of Werbie. She has been the CEO of Women's Health Specialists of St.Louis for the past 14 years. She is passionate about women's health both on a national and international level. She is also a consultant in the health tech space. She is a frequent guest on national TV, and has traveled the globe to promote women's health and wellness through lectures, symposiums, and medical missions. Currently, she has a monthly interview on a local television program called Great Day Saint Louis. She also lectures to resident physicians, consults for companies, and works internationally to help solve myriad challenges in the field of women's health.
Advanced Degree(s): MD OBGYN FACOG
Hi patients! We love you! We are 150% focused on YOU because by helping you succeed, doctors, care teams, hospitals, and insurers succeed. You drive the data for your care teams. We know that pregnancy is hard enough without diabetes. We're proud of the feedback from beta testers. “I am eating less carbs since I started using the system. The text messages remind me that I’m eating for my baby. I won’t have the cookie.” and “It was really helpful for me. Because you know someone is reinforcing what you’re doing is something important. The text messages encouraged me to log every time and giving someone my report felt like I was not only doing this for myself. By sharing my report, I can have feedback like I’m doing bad or good.”
Hi Physicians and Providers! Thank you. Thank you. Thank you. You are our heroes! You manage these high-risk cases and deliver positive outcomes everyday. Catherine Jones, CEO, had two high-risk pregnancies so she knows exactly how much work you do. She's a "NICU Mom" too, so she understands the incredible stress parents face when serious complications arise. What we hear from our in-house medical team and providers is that you need patient data in a quick-and-easy-to-digest format sent to you automatically every week or two, and on demand. We would love to partner with your clinics, hospitals and healthcare systems.
Hey there, hospitals! We hear your pain points over and over again and we want to help you. Your awesome medical teams are the ones managing high-risk pregnant patients and delivering babies day and night. Your staff - from MFMs, OBGYNs and endocrinologists to certified diabetes educators, nurses, and perinatal specialists - work to ensure positive outcomes to reduce the high costs of complications. In 2013, the combined hospitalization costs of women with GDM and pre-existing diabetes was more than $1.4 billion, or about 8.5% of all hospital costs associated with pregnancy care. That number does not include NICU stays and other complications. We welcome pilots with you to prove our system works. We’re open to all kinds of collaborations. Our main goal is to help you treat patients.
Hello Potential Partners - we're thinking you might be insurers, healthcare systems, and anyone interested in solving GDM! We’re eager to meet you. We know it’s often you who bear the high costs of GDM during pregnancy plus complications, both short and long term. You know that poorly managed blood glucose levels prior to conception are more likely to result in infants with congenital birth defects occurring in the first 8 weeks of development. Autism is also related to early unmanaged GDM. The effects of genetics in the role of GDM is a fascinating area of research that will have profound effects on future generations. Pregnancy is complicated. We don’t pretend to have a silver bullet, but we strongly believe that our GlucoseMama Kits are a much-need and urgent solution.
Werbie has an opportunity to enter into a TMO of at least 700K GDM patients: About 500,000 diagnosed with GDM during pregnancy and about 200,000 women with pre-existing diabetes (type 2) going into pregnancy every year. Our conservative estimate of 700K patients diagnosed with GDM is based the NCBI article, GDM: Risk and Management During and After Pregnancy, current statistics of up to 17% of the pregnant population depending on the type of diagnostic test used and the population studied. The occurrence of diabetes in women of childbearing age has doubled in the last 10 years, affecting 1.3 million women nationwide. According to the International Diabetes Federation, the global rate of GDM in 2015 was 212 million women. The GDM market is evergreen, renewing and growing every year as more women who are at-risk for GDM become pregnant.
In three years we intend to capture at least 10% of the market with revenues around $83M. With our clinical trial results and pilot studies, we will be in an excellent position to raise a seed round to capture 10% of the market by 2020. The international market is also on our radar.
Werbie is in the pre-revenue stage. We aim to establish paid pilots in 2018. Our B2B business model is focused on healthcare systems, insurance companies, hospitals, Medicaid, and payers as customers. Our benefit to them is two-fold: cost savings and improved outcomes. Distribution of the GlucoseMama Kits will be through doctors and nurse practitioners prescribing the kits to their patients with pre-existing diabetes or GDM. Down the road with clinical validation, reimbursement for the kits will ideally be bundled under one code.
We are 150% dedicated to helping under-served women on Medicaid. CMS has made diabetes management a key priority. The agency is evaluating software applications that may help manage Clinical Decision Support (CDS) for Electronic Health Records. In 2011, the FDA began compiling guidelines to map the approval process for software that CMS can use for certified diabetes educators. The FDA has delayed the publication of those guidelines. We will continue to pay close attention to these developments. With IRB data we are in an excellent position to take advantage of this and to meet any regulatory hurdles to stay competitive.
Our biggest competition is highly ineffective pen-and-paper logging. Our unique advantage in this space is that we understand the dynamic partnership that needs to exist between the patient + medical world + technology. We thoroughly understand the disease, and the pain points of all the stakeholders. With this deep knowledge, we have developed a product that services everyone.
We have an on-going clinical trial with the University of Maryland Medical Center. We have a pilot with MFM Associates of Maryland in the works. We are looking for pilots with hospitals, healthcare systems, and clinics.
If we win this challenge we would love to work with the wonderful people of New Orleans. The gestational diabetes rate in Louisiana is alarming and continues to rise. A report entitled, The Burden of Diabetes in Louisiana by the ADA, states that: “Approximately 521,294 people in Louisiana, or 13.9% of the adult population, have diabetes. Of these, an estimated 124,000 have diabetes but don’t know it, greatly increasing their health risk. In addition, 1,272,000 people in Louisiana, 37.5% of the adult population, have prediabetes with blood glucose levels higher than normal but not yet high enough to be diagnosed as diabetes. Every year an estimated 32,000 people in Louisiana are diagnosed with diabetes. Diabetes and prediabetes costs Louisiana $5.4 billion dollars each year.”
The pre-diabetes population, especially women of childbearing age, is the group that we are most concerned about. They are at risk for gestational diabetes and type 2 postpartum, and their children are at an increased risk for obesity and diabetes. We want to be a key player, along with other stakeholders in the healthcare system, to help these women self-manage their diabetes during pregnancy, and to offer educational tools and support for sustainable behavior change to prevent type 2. It would be an honor to officially launch the GlucoseMama Kits in New Orleans through pilots. PS: We know the food in New Orleans is totally amazing, so carb counting would be a constant challenge. But we’re up for it.
No updates found .